Theratechnologies Inc (THTX)

$THTX ready to pop

$THTX will be acquired by CB Biotech and expected to close 11/30/25. Weekly and Daily charts suggest this is a hold till then.

OS Therapies (NYSE-A: $OSTX) announced a series of clinical and regulatory milestones today. The company has secured an End-of-Phase 2 meeting with the U.S. Food and Drug Administration on 27 August 2025 to discuss a rolling Biologics License Application for its lead candidate, OST-HER2, in recurrent, pulmonary-metastatic osteosarcoma; it has also lined up parallel Scientific Advice meetings with the European Medicines Agency and the UK Medicines & Healthcare products Regulatory Agency to advance OST-HER2 through centralized EU and ILAP pathways. In addition, all patients in the Phase 1 study of OST-504 for second-line prostate cancer have completed treatment, with updated data expected later in 2025. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/os-therapies-1 The update highlights management’s plan to secure U.S. approval before the Rare Pediatric Disease Priority Review Voucher program sunsets, potentially generating non-dilutive capital from a future PRV sale to fund OST-HER2 commercialization and advance additional pipeline candidates. Highlights from the news release include: - FDA End-of-Phase 2 meeting for OST-HER2 set for 27 August 2025, with the goal of agreeing on a rolling BLA submission under Accelerated Approval. - Scientific Advice engagements secured with EMA and UK regulators, paving the way for EU centralized approval and UK Conditional Marketing Authorization via ILAP. - Phase 1 OST-504 prostate-cancer trial fully treated; clinical data expected in the second half of 2025. Paul Romness, MPH, Chairman & CEO of OS Therapies, noted, “We are making significant progress towards our primary objective of obtaining regulatory approval for OST-HER2 in recurrent, pulmonary metastatic osteosarcoma prior to the sunsetting of the rare pediatric disease priority review voucher (“PRV”) program. If successful, we expect to receive significant non-dilutive funding from the sale of the PRV which we would then be able to deploy in commercializing OST-HER2 osteosarcoma and other HER2 expressing cancers, as well as advance the other clinical candidates in our pipeline, including OST-504 in prostate cancer. We strongly believe in the promise of the listeria immunotherapy platform to help prevent and treat cancer, and intend to judiciously deploy our capital to focus on the OST-HER2 approval while advancing our other clinical programs without deploying significant capital or running other clinical studies while we wait for the OST-HER2 approval and related PRV sale.” Full release: https://ir.ostherapies.com/news-events/press-releases/detail/69/os-therapies-provides-clinical-global-regulatory-updates. Led by Paul Romness and an experienced executive team that includes Christopher Acevedo, Robert Petit, John Doll, and Gerald Commissiong, OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other cancers. Disclosure: The management of B2i Digital owns unrestricted shares of OSTX stock purchased in the open market. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/os-therapies-1. $THTX, $CGTX

$THTX SUGP contract big win!!

$THTX Theratechnologies Q2 2025 Sales $17.73M Beat $17.55M Estimate, Net Loss Of $4.46M Vs. Profit Of $987K YoY

#earnings after the close on Tuesday, July 8, 2025 and before the open on Wednesday, July 9, 2025 https://www.earningswhispers.com/calendar $PENG $THTX $KRUS $SAR $AEHR

Earnings tomorrow: $AZZ $PCYO $BSET $THTX View the entire list here: https://stockanalysis.com/stocks/earnings-calendar/?ref=saveontrading

$THTX sold all, don't like waiting. Good luck with the CVR

$THTX Why should I keep my shares? If they got bought out at around 3.01/share, we shouldn't expect the SP to move much anymore, right ?

$THTX hhhhhh you are right..